- Home
- ASO vs AAPG Comparison
ASO vs AAPG Comparison
Compare ASO & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- AAPG
- Stock Information
- Founded
- ASO 1938
- AAPG 2009
- Country
- ASO United States
- AAPG China
- Employees
- ASO N/A
- AAPG 567
- Industry
- ASO Recreational Games/Products/Toys
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- ASO Consumer Discretionary
- AAPG Health Care
- Exchange
- ASO Nasdaq
- AAPG Nasdaq
- Market Cap
- ASO 2.5B
- AAPG 2.2B
- IPO Year
- ASO 2020
- AAPG 2025
- Fundamental
- Price
- ASO $39.22
- AAPG $24.21
- Analyst Decision
- ASO Buy
- AAPG Buy
- Analyst Count
- ASO 18
- AAPG 1
- Target Price
- ASO $58.00
- AAPG N/A
- AVG Volume (30 Days)
- ASO 1.4M
- AAPG 32.5K
- Earning Date
- ASO 06-10-2025
- AAPG 05-20-2025
- Dividend Yield
- ASO 1.31%
- AAPG N/A
- EPS Growth
- ASO N/A
- AAPG N/A
- EPS
- ASO 5.73
- AAPG N/A
- Revenue
- ASO $5,933,450,000.00
- AAPG $134,352,180.00
- Revenue This Year
- ASO $4.71
- AAPG N/A
- Revenue Next Year
- ASO $6.78
- AAPG $389.09
- P/E Ratio
- ASO $6.91
- AAPG N/A
- Revenue Growth
- ASO N/A
- AAPG 341.77
- 52 Week Low
- ASO $33.34
- AAPG $16.50
- 52 Week High
- ASO $64.62
- AAPG $26.50
- Technical
- Relative Strength Index (RSI)
- ASO 48.62
- AAPG N/A
- Support Level
- ASO $37.01
- AAPG N/A
- Resistance Level
- ASO $40.37
- AAPG N/A
- Average True Range (ATR)
- ASO 1.28
- AAPG 0.00
- MACD
- ASO 0.60
- AAPG 0.00
- Stochastic Oscillator
- ASO 73.98
- AAPG 0.00
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.